MIRM Mirum Pharmaceuticals, Inc.
Healthcare$98.90+0.28%ClosedMarket Cap: $4.96B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
23.93
P/S
8.69
EV/EBITDA
-129.11
DCF Value
$-3,336.68
FCF Yield
-3.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
81.4%
Operating Margin
-12.3%
Net Margin
-140.2%
ROE
-289.3%
ROA
-89.7%
ROIC
-11.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $159.9M | 81.9% | $-63.2M | $-790.2M | $— | — |
| Q4 null | $148.9M | 81.0% | $-4.6M | $-5.7M | $— | — |
| FY null | $521.3M | 80.7% | $-22.1M | $-23.4M | $— | — |
| Q3 null | $133.0M | 80.8% | $2.6M | $2.9M | $— | — |
| Q2 null | $127.8M | 81.7% | $-5.0M | $-5.9M | $— | — |
| Q1 null | $111.6M | 79.4% | $-15.2M | $-14.7M | $— | — |
| Q4 null | $99.4M | 77.1% | $-24.2M | $-23.8M | $— | — |
| FY null | $336.9M | 75.8% | $-87.6M | $-87.9M | $— | — |
| Q3 null | $90.4M | 77.0% | $-12.7M | $-14.2M | $— | — |
| Q2 null | $77.9M | 74.0% | $-24.2M | $-24.6M | $— | — |
| Q1 null | $69.2M | 74.2% | $-26.5M | $-25.3M | $— | — |
| Q4 2023 | $69.6M | 64.0% | $-32.6M | $-35.7M | $-0.71 | — |